Researchers launch combination drug trial to eradicate B-cell malignancies

March 9, 2018, University of California - San Diego
UC San Diego Researchers launch combination drug trial to eradicate B-cell malignancies
Stained blood smear shows enlarged chronic lymphocytic leukemia cells among normal red blood cells. Credit: UC San Diego Health

Fueled by a multimillion dollar grant from the state's stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.

The approach combines an experimental monoclonal antibody-based drug called cirmtuzumab with ibrutinib, a small molecule drug that inhibits Bruton's tyrosine kinase, a protein that promotes cell survival and growth. Ibrutinib, marketed as Imbruvica, is already approved to treat B-cell cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Cirmtuzumab targets ROR1, a cell surface protein present on tumors but not on normal adult tissues—a distinction that makes it an attractive target for anticancer therapy. Cirmtuzumab is currently in for the treatment of CLL.

The objectives of the trial are to determine the safety of the combination, the optimal dose and regimen, and the duo's effectiveness compared to treatment with ibrutinib alone. "Specifically, we'll evaluate whether adding cirmtuzumab leads to more patients achieving a complete response compared to just ibrutinib," said Michael Choi, MD, assistant clinical professor and a member of the trial team led by principal investigator Catriona Jamieson, MD, PhD, deputy director of the Sanford Stem Cell Clinical Center at UC San Diego Health and director of at UC San Diego Moores Cancer Center.

"This is an important advance," said Thomas Kipps, MD, PhD, Distinguished Professor of Medicine and deputy director of research at UC San Diego Moores Cancer Center, whose lab developed cirmtuzumab. "Although ibrutinib is standard of care for patients with CLL or MCL, it is exceptionally rare for the drug by itself to completely eradicate all leukemia cells or produce long-lasting remissions in CLL without continuous therapy."

"As a result, patients typically need to take ibrutinib indefinitely, or until they develop intolerance or resistance to this drug. Cirmtuzumab targets leukemia and , which are like the seeds of cancer. They are hard to find and difficult to destroy. By blocking signaling pathways that promote neoplastic-cell growth and survival, cirmtuzumab may have complementary activity with ibrutinib in killing leukemia cells, allowing patients potentially to achieve complete remissions that permit patients to stop therapy altogether."

The trial has started enrolling participants, with a goal of 117 at 15 sites across the United States, including the Alpha Stem Cell Clinic at UC San Diego Health, one of five advanced clinics in a network designated by the California Institute for Regenerative Medicine (CIRM), which warded the research team $18.29 million last year to conduct the clinical trial, scheduled to be completed in 2022.

"The CIRM Alpha Stem Cell clinic provides additional staff support to the cancer research team and through its network facilitates the trial at other institutions in the state, making access to this innovative cancer stem cell targeted product and opportunity available to a large proportion of California residents," said Jamieson.

"It's an exciting next step for cirmtuzumab," said Ingrid Caras, PhD, CIRM's senior science officer and associate director for therapeutics. "Our partnership with UC San Diego and the alpha stem cell clinics has enabled this trial to more quickly engage potential patient-participants. Being among the first to try new therapies requires courage and CIRM is grateful to the patients who are volunteering to be part of this clinical trial."

The trial is being conducted in collaboration with Oncternal Therapeutics, a San Diego-based clinical stage biotech specializing in first-in-class and novel therapeutics for both rare and common cancers.

B-cell malignancies are cancers of the blood. B-cells are a type of white blood cell or lymphocyte. They are part of the immune system. Some B cells produce antibodies to immediately help fight off infections while others, called memory B-cells, "remember" the pathogen in case of future infections. In B-cell cancers, mutated B- dysfunction or grow in an uncontrolled manner, resulting in diseases like CLL (the most common type of leukemia) and most non-Hodgkin's lymphomas.

Cirmtuzumab has also shown efficacy against solid tumors. A clinical trial is planned to test it, in combination with the drug paclitaxel, for treating metastatic breast cancer. That trial is not yet recruiting participants. Cirmtuzumab's name is a nod to CIRM's long-standing support and research funding.

Explore further: Novel drug targeting leukemia cells enters clinical trial

Related Stories

Novel drug targeting leukemia cells enters clinical trial

September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia ...

Clinical trial to test safety of drug targeting leukemia cells

September 3, 2014
Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, ...

Protein-protein interaction activates and fuels leukemia cell growth

December 21, 2015
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 ...

Drug combination yields results in patients with forms of leukemia or lymphoma

December 5, 2016
A combination of two targeted agents - one approved by the Food and Drug Administration and one undergoing testing - has demonstrated safety as well as encouraging signs of effectiveness in a phase 1 clinical trial in patients ...

Anti-leukemia drug may also work against ovarian cancer

November 17, 2014
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer - and likely other cancers as well, report researchers at the University of California, ...

Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia

December 11, 2017
Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with ...

Recommended for you

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.